Provided by Tiger Fintech (Singapore) Pte. Ltd.

Candel Therapeutics, Inc.

5.95
+0.16002.76%
Volume:681.71K
Turnover:4.10M
Market Cap:326.63M
PE:-11.40
High:6.18
Open:5.84
Low:5.80
Close:5.79
52wk High:14.60
52wk Low:3.79
Shares:54.90M
Float Shares:45.48M
Volume Ratio:1.01
T/O Rate:1.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5221
EPS(LYR):-1.7420
ROE:-55.18%
ROA:-33.39%
PB:3.62
PE(LYR):-3.42

Loading ...

BRIEF-Candel Therapeutics Extends Lease Term To Aug 31, 2029

Reuters
·
Aug 22

Candel Therapeutics Inc - on Aug 18, Extended Lease Term to Aug 31, 2029

THOMSON REUTERS
·
Aug 22

Candel Therapeutics Inc. Extends Lease Agreement for Needham Premises Until 2029

Reuters
·
Aug 22

Candel Therapeutics Advances with Promising Cancer Therapies

TIPRANKS
·
Aug 19

Candel Therapeutics Inc. Unveils Corporate Presentation Highlighting Advances in Cancer Immunotherapy and Promising Clinical Trial Results

Reuters
·
Aug 15

Candel Therapeutics Inc Files for Mixed Shelf of Upto $300 Mln - SEC Filing

THOMSON REUTERS
·
Aug 14

Candel Therapeutics reports Q2 EPS (9c) vs. (74c) last year

TIPRANKS
·
Aug 14

Candel Therapeutics Reports Increased R&D Expenses in Q2 2025, Highlights FDA RMAT Designation for Prostate Cancer Treatment CAN-2409

Reuters
·
Aug 14

BRIEF-Candel Therapeutics Q2 Net Income USD -4.796 Million

Reuters
·
Aug 14

Candel Therapeutics' Chief Medical Officer William Garrett Nichols Reports Disposal of Common Shares

Reuters
·
Jul 31

Candel Therapeutics to Present at Canaccord Genuity 45th Annual Growth Conference

Reuters
·
Jul 30

Candel Therapeutics Secures EMA Orphan Designation for CAN-2409 in Pancreatic Cancer Treatment

Reuters
·
Jul 24

Candel Therapeutics Receives Ema Orphan Designation for Can-2409 for the Treatment of Pancreatic Cancer

THOMSON REUTERS
·
Jul 24

Candel Therapeutics: Promising Phase 3 Data and Strong Financial Runway Justify Buy Rating

TIPRANKS
·
Jul 23

Candel Therapeutics initiated with a Buy at Brookline

TIPRANKS
·
Jul 10

Candel Therapeutics Joins Multiple Russell Value Indexes in 2025 Reconstitution

Reuters
·
Jul 09

Candel Therapeutics Inc. Chief Medical Officer William Garrett Nichols Reports Disposal of Common Shares

Reuters
·
Jul 03

Candel Therapeutics Announces $15M Stock Offering

TIPRANKS
·
Jun 24

BRIEF-Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Reuters
·
Jun 24

Candel Therapeutics Files Prospectus for $15 Million Direct Stock Offering to Advance Cancer Therapy Development

Reuters
·
Jun 24